The Line Just Moved: USEF Cetirizine and Drug Rule Changes

There is a small absurdity that has repeated itself every summer across the hunter/jumper circuit. A horse breaks out in hives -- raised, hot welts along the neck and barrel, triggered by insect bites, by pollen, by the particular chemistry of the horse's own immune system -- and the veterinarian prescribes cetirizine, the second-generation antihistamine sold to humans as Zyrtec and administered routinely in equine practice for precisely this purpose, which works. It reduces the allergic response without sedating the horse. And then, if the horse is showing that weekend, the trainer stops giving it. Files a Medication Report Form. Observes a twenty-four-hour withdrawal. Sends the horse into the ring without its allergy medication, because the regulations classified cetirizine alongside drugs that can genuinely alter performance.

On July 27, in the middle of peak show season, US Equestrian ended that requirement. Cetirizine is now a permitted substance. Effective immediately, it may be used in competition without restriction. No medication report form. No withdrawal period. No penalty. And for every positive test for cetirizine in the 2026 competition year, the case will be dropped and any collected fines refunded.

What a second generation means

The regulatory history of cetirizine in USEF competition is a case study in a classification catching up to the pharmacology. Under the prior rules, cetirizine was treated as a Category IIa substance -- the same tier that covers prohibited medications with legitimate therapeutic uses but a recognised capacity to affect the horse's competitive state. The problem was one of inheritance: cetirizine was regulated identically to first-generation antihistamines such as hydroxyzine and diphenhydramine, which cross the blood-brain barrier and can produce drowsiness. The sedating effect of those older drugs is precisely why they were controlled. A sedated horse handles differently, and the rules existed to prevent pharmacological influence on performance.

Cetirizine does not cross that barrier. It is a second-generation H1-receptor antagonist that does not readily penetrate the central nervous system and does not produce apparent sedative effects in horses. Research from the Swedish University of Agricultural Sciences in Uppsala established its basic pharmacokinetic profile in horses nearly two decades ago: after oral administration at 0.2 mg/kg, the mean terminal half-life was 3.4 hours, with no clinically observed sedation (Olsen, Ingvast-Larsson, Bondesson, Brostrom, Tjalve, and Larsson, Journal of Veterinary Pharmacology and Therapeutics, 2007). A subsequent study at the University of California, Davis, examined nine exercised Thoroughbreds receiving cetirizine at 0.4 mg/kg twice daily and reported a serum elimination half-life of 5.83 hours, with the drug still detectable in serum at trace concentrations forty-eight hours after the final dose -- but with no performance-altering properties identified at any point in the trial (Knych and Stanley, Journal of Veterinary Pharmacology and Therapeutics, 2016).

The irony is pharmaceutical. Cetirizine is the active metabolite of hydroxyzine -- the very first-generation antihistamine whose sedating effects justify its controlled status. When a horse receives hydroxyzine, its liver converts a portion into cetirizine, the compound that does the therapeutic work without the central nervous system depression. The regulation was penalising the molecule that separated the treatment from the side effect.

What hives cost in July

The practical significance of this reclassification arrives at the moment of the year when it matters most. Allergic skin disease is the most common dermatological condition in horses. The World Association for Veterinary Dermatology published its first evidence-based clinical consensus guidelines on equine allergic skin diseases in 2023, identifying insect bite hypersensitivity, atopic dermatitis, and chronic urticaria as conditions affecting horses across every breed and discipline, with the highest clinical burden concentrated in the warm months (Marsella and colleagues, Veterinary Dermatology, 2023). Insect bite hypersensitivity alone -- triggered primarily by the saliva of Culicoides midges -- has a reported prevalence of three to ten per cent across European horse populations, and the UC Davis Center for Equine Health identifies it as the most common pruritic disease of the species.

For the show horse in mid-summer, the arithmetic has been simple and punishing. Hives or a flare of insect bite hypersensitivity on Tuesday. A veterinarian prescribes cetirizine on Wednesday. The horse responds -- the wheals flatten, the itching subsides, the horse stops rubbing its mane and tail. The horse is entered on Saturday. The cetirizine stops on Friday, the Medication Report Form is filed, the twenty-four-hour withdrawal begins, and by Saturday morning the allergic response is returning. The medication that kept the horse comfortable was withdrawn not because it posed a risk to the competition but because the regulatory framework had not distinguished it from drugs that do.

The USEF Veterinary Committee's decision to reclassify cetirizine as permitted -- and to retroactively drop all 2026 positive findings and refund associated fines -- acknowledges that this distinction should have been drawn earlier. It is a correction, not an innovation.

The methocarbamol refinement

Alongside the cetirizine reclassification, US Equestrian updated its guidance on methocarbamol, a centrally acting muscle relaxant commonly prescribed for acute muscle injury and exertional rhabdomyolysis -- the condition known in every barn as tying up. Methocarbamol remains a controlled substance, but the withdrawal recommendations have been refined to reflect the drug's actual behaviour. If methocarbamol is the only medication the horse is receiving and the horse is not on any dietary supplement, the recommended withdrawal prior to competition is twelve hours. If the horse is receiving any other medication or supplement alongside methocarbamol, the withdrawal extends to twenty-four hours.

The distinction reflects the pharmacokinetics. Methocarbamol has a plasma half-life of sixty to ninety minutes in horses -- far shorter than most substances on the controlled list. The concern is not the drug in isolation but how it interacts metabolically with other compounds in the horse's system. A twelve-hour window for a drug with a ninety-minute half-life is generous by any pharmacokinetic standard; the twenty-four-hour window when other substances are present provides additional margin against interactions the science has not fully characterised. Like the cetirizine change, the methocarbamol guidance represents the federation drawing finer regulatory lines -- not softer ones, but more pharmacologically precise ones.

A harder line, a cleaner one

These changes arrive in a regulatory environment that has simultaneously become stricter. For samples collected after May 31, 2026 -- under rules approved by the USEF Board of Directors in February -- any positive finding for a Category II, III, or IV substance now carries not only the standard penalties for the responsible person but a mandatory suspension of the horse itself. If a horse tests positive for acepromazine, a Category IIb sedative, and the trainer receives a two-month suspension, the horse is also suspended for two months. It cannot compete regardless of who trains it during that period. The intent is to ensure that the consequences of a drug violation follow the animal, not just the licence, and to give owners a direct incentive to oversee the medications their horses receive.

What the cetirizine reclassification and the horse suspension rule together represent is a federation learning to distinguish between the medicine cabinet and the controlled list -- between the antihistamine that keeps a horse comfortable and the sedative that masks its condition. The first now belongs in the show barn without penalty. The second carries consequences that are harder to absorb, harder to delegate, and harder to repeat.

The category system governing equine drugs and medications at USEF-licensed competitions has always carried an implicit tension. Category I comprises permitted therapeutic substances. Category II comprises prohibited substances with legitimate therapeutic uses. The distance between those two designations -- between a substance a horse may have in its system during competition and one it may not -- is not always a pharmacological one. It has sometimes been an administrative artefact, a legacy of an era when the classification defaulted to restriction. Cetirizine spent years in Category II not because it altered performance but because it belonged to a drug class whose older members did. The reclassification is an acknowledgment that the class should not be the unit of regulation. The molecule should be.

For the sport-horse owner navigating the current system, the practical guidance is straightforward. Cetirizine may be administered without interruption through competition. Methocarbamol requires a twelve- or twenty-four-hour withdrawal depending on what else the horse is receiving. And the stakes of a positive finding for any substance that remains on the prohibited list -- including first-generation antihistamines, sedatives, and any Category II, III, or IV substance -- are higher than they were before June, because the horse is now suspended alongside the trainer. The line moved. In both directions at once.